This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Connors, J. M. Search for Related Content PubMed PubMed Citation Articles by Connors, J. M. Social Bookmarking                            What's this?

State-of-the-Art Therapeutics: Hodgkin's Lymphoma

Joseph M. Connors

From the Lymphoma Tumor Group; and the British Columbia Cancer Agency; the University of British Columbia, Vancouver, BC Canada

Address reprint requests to Joseph M. Connors, MD, British Columbia Cancer Agency, 600 W 10^th Avenue, Vancouver, BC Canada V5Z 4E6; e-mail: jconnors{at}bccancer.bc.ca.

Presently Hodgkin's lymphoma can be cured in at least 80% of patients. The major challenge to the clinician in 2005 is how to cure the disease while inducing the least irreversible toxicity. This review focuses on clinical trials and institutional experiences to identify the best choice of treatment, individualized to the stage of the lymphoma permitting minimization of late toxicity such as infertility, premature menopause, cardiac disease, and most importantly, risk of second neoplasms. More than 90% of patients with limited Hodgkin's lymphoma can be cured with either short-course chemotherapy alone or even briefer chemotherapy followed by involved-field radiation. Accumulating evidence suggests that chemotherapy alone is suitable for the large majority of patients with limited disease. For the 80% of patients with advanced disease but without a large number of adverse prognostic factors, standard multi-agent chemotherapy with the well-established ABVD regimen (doxorubicin, bleomycin, vinblastine, and dacarbazine) provides the best balance of effectiveness and minimization of toxicity. More intensified regimens currently under investigation are appropriate for the 20% with numerous adverse prognostic factors. In 2005 it is insufficient to focus solely on cure of Hodgkin's lymphoma. The treatment program must maximize chance of cure and minimize late toxicity. Fortunately, brief chemotherapy alone or with radiation for patients with limited disease and standard ABVD chemotherapy for patients with advanced disease offer the appropriate balance of these two requirements. Patients with advanced disease plus multiple indicators of a poor prognosis and patients with disease that persists despite optimized primary treatment require specially intensified treatment.

Author's disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. Delbeke, S. Stroobants, E. de Kerviler, C. Gisselbrecht, M. Meignan, and P. S. Conti Expert Opinions on Positron Emission Tomography and Computed Tomography Imaging in Lymphoma Oncologist, October 1, 2009; 14(suppl_2): 30 - 40. [Abstract] [Full Text] [PDF]

				T. Terasawa, J. Lau, S. Bardet, O. Couturier, T. Hotta, M. Hutchings, T. Nihashi, and H. Nagai Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review J. Clin. Oncol., April 10, 2009; 27(11): 1906 - 1914. [Abstract] [Full Text] [PDF]

				V. Ribrag, S. Koscielny, O. Casasnovas, C. Cazeneuve, P. Brice, F. Morschhauser, J. Gabarre, A. Stamatoullas, G. Lenoir, G. Salles, et al. Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis Blood, April 2, 2009; 113(14): 3307 - 3313. [Abstract] [Full Text] [PDF]

				E. Brusamolino, A. Bacigalupo, G. Barosi, G. Biti, P. G. Gobbi, A. Levis, M. Marchetti, A. Santoro, P. L. Zinzani, and S. Tura Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up Haematologica, April 1, 2009; 94(4): 550 - 565. [Abstract] [Full Text] [PDF]

				E. T. Chang, B. M. Birmann, J. L. Kasperzyk, D. V. Conti, P. Kraft, R. F. Ambinder, T. Zheng, and N. E. Mueller Polymorphic Variation in NFKB1 and Other Aspirin-Related Genes and Risk of Hodgkin Lymphoma Cancer Epidemiol. Biomarkers Prev., March 1, 2009; 18(3): 976 - 986. [Abstract] [Full Text] [PDF]

				B. Sanchez-Espiridion, A. Sanchez-Aguilera, C. Montalban, C. Martin, R. Martinez, J. Gonzalez-Carrero, C. Poderos, C. Bellas, M. F. Fresno, C. Morante, et al. A TaqMan Low-Density Array to Predict Outcome in Advanced Hodgkin's Lymphoma Using Paraffin-Embedded Samples Clin. Cancer Res., February 15, 2009; 15(4): 1367 - 1375. [Abstract] [Full Text] [PDF]

				K. D. Goodwin, M. A. Lewis, E. C. Long, and M. M. Georgiadis Crystal structure of DNA-bound Co(III){middle dot}bleomycin B2: Insights on intercalation and minor groove binding PNAS, April 1, 2008; 105(13): 5052 - 5056. [Abstract] [Full Text] [PDF]

				T. C. Kwee, R. M. Kwee, and R. A. J. Nievelstein Imaging in staging of malignant lymphoma: a systematic review Blood, January 15, 2008; 111(2): 504 - 516. [Abstract] [Full Text] [PDF]

				D. A. Macdonald, K. Ding, M. K. Gospodarowicz, W. A. Wells, R. G. Pearcey, J. M. Connors, J. N. Winter, S. J. Horning, M. S. Djurfeldt, L. E. Shepherd, et al. Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphoma Ann. Onc., October 1, 2007; 18(10): 1680 - 1684. [Abstract] [Full Text] [PDF]

				A. Engert, J. Franklin, H. T. Eich, C. Brillant, S. Sehlen, C. Cartoni, R. Herrmann, M. Pfreundschuh, M. Sieber, H. Tesch, et al. Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial J. Clin. Oncol., August 10, 2007; 25(23): 3495 - 3502. [Abstract] [Full Text] [PDF]

				E. Brusamolino, A. Baio, E. Orlandi, L. Arcaini, F. Passamonti, V. Griva, W. Casagrande, C. Pascutto, P. Franchini, and M. Lazzarino Long-term Events in Adult Patients with Clinical Stage IA-IIA Nonbulky Hodgkin's Lymphoma Treated with Four Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Adjuvant Radiotherapy: A Single-Institution 15-Year Follow-up. Clin. Cancer Res., November 1, 2006; 12(21): 6487 - 6493. [Abstract] [Full Text] [PDF]

				M. K. Gospodarowicz and R. M. Meyer The Management of Patients with Limited-Stage Classical Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 253 - 258. [Abstract] [Full Text] [PDF]